CAR-T细胞治疗在血液系统恶性肿瘤中的研究进展

The research development of Chimeric Antigen Receptor T-cells in hematological malignancies

嵌合抗原受体T(CAR-T)细胞是近年来迅速发展的肿瘤过继性免疫治疗新手段。其主要特点是通过基因工程改造获得识别肿瘤抗原特异性受体的T细胞并赋予其靶向性、杀伤性及持久性的治疗方法。1989年首次提出CAR-T,现已经发展到第四代,且多研究中心对CD19-CAR-T细胞治疗技术进行了I期临床研究显示出活性。CAR-T疗法是目前有望治愈复发难治性血液肿瘤的新方法。

In recent years,chimeric antigen receptor T -cells（CAR-T cells）therapy becomes the new rapid development of adoptive tumor immunotherapy .Its main characteristic is to identify specific T cell receptor of tumor antigen by genetic engineering modification and give its targeting ,killing and persistent treatment .The CAR-T was mentioned for the first time in 1989,and has developed to the fourth generation .CD19-CAR-T treatment technique shows activity in phase I clinical trials of multiple research centers .CAR-T therapy is ex-pected as a new way to cure relapse/refractory hematological malignancies .